Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.65 |
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30110196 | 0.81 | MAOB (1.00) | MAOBGPR35MAOAALDH1A1HPGD | |
| SCHEMBL17037289 | 0.81 | MAOB (1.00) | MAOBGPR35MAOAALDH1A1HPGD | |
| SCHEMBL1367003 | 0.81 | GPR35 (0.79) | MAOBGPR35MAOAALDH1A1HPGD | |
| SCHEMBL3091303 | 0.80 | MAOB (0.77) | MAOBGPR35MAOAALDH1A1HPGD | |
| SCHEMBL3080344 | 0.79 | GPR35 (1.00) | MAOBGPR35MAOAALDH1A1HPGD | |
| SCHEMBL30110368 | 0.78 | GPR35 (0.74) | MAOBGPR35MAOAALDH1A1HPGD | |
| SCHEMBL3065914 | 0.78 | TSHR (0.71) | GPR35MAOAALDH1A1HPGDLMNA | |
| SCHEMBL27562487 | 0.74 | GPR35 (0.75) | MAOBGPR35MAOAALDH1A1HPGD | |
| SCHEMBL27562485 | 0.72 | GPR35 (0.56) | MAOBGPR35MAOAALDH1A1HPGD | |
| SCHEMBL13561369 | 0.70 | LMNA (1.00) | MAOBGPR35MAOAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825261-A1 | POLYPEPTIDES AND THEIR USE | Novabiotics Limited (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-20140155321-A1 | Polypeptides and Their Use | NOVABIOTICS LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| WO-2013136040-A1 | POLYPEPTIDES AND THEIR USE | NOVABIOTICS LIMITED (GB) | 2013-09-19 | — | — | WO | disclosed |
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | DPM1, XPO5, NISCH | MAOB 3597/4885GPR35 4086/4885MAOA 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.